Biological therapies targeting the type 2 inflammatory pathway in severe asthma (Review)
- Authors:
- Ariadna Petronela Fildan
- Ruxandra-Mioara Rajnoveanu
- Roxana Cirjaliu
- Ionela Pohrib
- Emanuela Tudorache
- Adrian Cosmin Ilie
- Cristian Oancea
- Doina Tofolean
-
Affiliations: Faculty of Medicine, Ovidius University, Constanța 900527, Romania, Department of Pneumology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj‑Napoca 400371, Romania, Department of Pneumology, Victor Babes University of Medicine and Pharmacy, Timisoara 300041, Romania - Published online on: September 6, 2021 https://doi.org/10.3892/etm.2021.10698
- Article Number: 1263
-
Copyright: © Fildan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Global Initiative for Asthma. Global strategy for asthma management and prevention, 2021. Available from: https://ginasthma.org/gina-reports/. Accessed August 12, 2021. | |
|
The Global Asthma Report 2018. Auckland, New Zealand: Global asthma network. Available from: https://theunion.org/technical-publications/the-global-asthma-report-2018 http://globalasthmanetwork.org/. Accessed December 13, 2020. | |
|
D'Amato G, Vitale C, Molino A, Stanziola A, Sanduzzi A, Vatrella A, Mormile M, Lanza M, Calabrese G, Antonicelli L and D'Amato M: Asthma-related deaths. Multidiscip Respir Med. 11(37)2016.PubMed/NCBI View Article : Google Scholar | |
|
GINA Pocket Guide 2019. Difficult to treat and severe asthma in adults and adolescents. Available from: https://ginasthma.org/wp-content/uploads/2019/04/GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1.pdf. Accessed September 10, 2020. | |
|
Munteanu LA, Fildan AP, Tudorache E, Fira-Mladinescu O, Frandes M, Timar B, Oancea C and Tofolean DE: Inhaler technique errors in Romanian patients with asthma-a multicenter study. Patient Prefer Adherence. 13:1401–1414. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Pavord ID, Shrimanker R and Hanania NA: Biologics targeting type 2 inflammation. In: Severe Asthma (ERS Monograph). Chung KF, Israel E and Gibson PG (eds). European Respiratory Society, Sheffield, pp285-303, 2019. | |
|
Busse WW: Biological treatments for severe asthma: A major advance in asthma care. Allergol Int. 68:158–166. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Robinson D, Humbert M, Buhl R, Cruz AA, Inoue H, Korom S, Hanania NA and Nair P: Revisiting type 2-high and type 2-low airway inflammation in asthma: Current knowledge and therapeutic implications. Clin Exp Allergy. 47:161–175. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Stokes JR and Casale TB: Characterization of asthma endotypes: Implications for therapy. Ann. Allergy Asthma Immunol. 117:121–125. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Sze E, Bhalla A and Nair P: Mechanisms and therapeutic strategies for non-T2 asthma. Allergy. 75:311–325. 2020.PubMed/NCBI View Article : Google Scholar | |
|
McGregor MC, Krings JG, Nair P and Castro M: Role of biologics in asthma. Am J Respir Crit Care Med. 199:433–445. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Krings JG, McGregor MC, Bacharier LB and Castro M: Biologics for severe asthma: Treatment-specific effects are important in choosing a specific agent. J Allergy Clin Immunol Pract. 7:1379–1392. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Tan R, Liew MF, Lim HF, Leung BP and Wong WSF: Promises and challenges of biologics for severe asthma. Biochem Pharmacol. 179(114012)2020.PubMed/NCBI View Article : Google Scholar | |
|
Eger KA and Bel EH: The emergence of new biologics for severe asthma. Curr Opin Pharmacol. 46:108–115. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Pavord ID, Beasley R, Agusti A, Anderson GP, Bel E, Brusselle G, Cullinan P, Custovic A, Ducharme FM, Fahy JV, et al: After asthma: Redefining airways diseases. Lancet. 391:350–400. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Rogliani P, Calzetta L, Matera MG, Laitano R, Ritondo BL, Hanania NA and Cazzola M: Severe asthma and biological therapy: When, which, and for whom. Pulm Ther. 6:47–66. 2020.PubMed/NCBI View Article : Google Scholar | |
|
De Ferrari L, Chiappori A, Bagnasco D, Riccio AM, Passalacqua G and Canonica GW: Molecular phenotyping and biomarker development: Are we on our way towards targeted therapy for severe asthma? Expert Rev Respir Med. 10:29–38. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Kuruvilla ME, Lee FE and Lee GB: Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 56:219–233. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Bernstein JA and Panettieri R Jr: Treatment of severe, uncontrolled eosinophilic asthma: Where we are heading. J Asthma. 56:459–472. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Voehringer D, Reese TA, Huang X, Shinkai K and Locksley RM: Type 2 immunity is controlled by IL-4/IL-13 expression in hematopoietic non-eosinophil cells of the innate immune system. J Exp Med. 203:1435–1446. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Chang YJ, Kim HY, Albacker LA, Baumgarth N, McKenzie AN, Smith DE, Dekruyff RH and Umetsu DT: Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol. 12:631–638. 2011.PubMed/NCBI View Article : Google Scholar | |
|
King GG, James A, Harkeness L and Warki P: Pathophysiology of severe asthma: We've only just started. Respirology. 23:262–271. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Brusselle GG, Maes T and Bracke KR: Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma. Nat Med. 19:977–979. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Bakakos A, Loukides S and Bakakos P: Severe eosinophilic asthma. J Clin Med. 8(1375)2019.PubMed/NCBI View Article : Google Scholar | |
|
Dunican EM, Elicker BM, Gierada DS, Nagle SK, Schiebler ML, Newell JD, Raymond WW, Lachowicz-Scroggins ME, Di Maio S, Hoffman EA, et al: Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest. 128:997–1009. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Schulman ES: Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med. 164:S6–S11. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, Gruchalla RS, Kattan M, Teach SJ, Pongracic JA, et al: Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 364:1005–1015. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA and Busse W: Omalizumab in severe allergic asthma inadequately controlled with standard therapy: A randomized trial. Ann Intern Med. 154:573–582. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM and Busse W: Exploring the effects of omalizumab in allergic asthma: An analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 187:804–811. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Ledford D, Busse W, Trzaskoma B, Omachi TA, Rosén K, Chipps BE, Luskin AT and Solari PG: A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 140:162–169.e2. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Humbert M, Taillé C, Mala L, Le Gros V, Just J and Molimard M: STELLAIR investigators. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: The STELLAIR study. Eur Respir J. 51(1702523)2018.PubMed/NCBI View Article : Google Scholar | |
|
Casale TB, Luskin AT, Busse W, Zeiger RS, Trzaskoma B, Yang M, Griffin NM and Chipps BE: Omalizumab effectiveness by biomarker status in patients with asthma: Evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract. 7:156–164.e1. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Esquivel A, Busse WW, Calatroni A, Togias AG, Grindle KG, Bochkov YA, Gruchalla RS, Kattan M, Kercsmar CM, Khurana Hershey G, et al: Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma. Am J Respir Crit Care Med. 196:985–992. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Gill MA, Liu AH, Calatroni A, Krouse RZ, Shao B, Schiltz A, Gern JE, Togias A and Busse WW: Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. J Allergy Clin Immunol. 141:1735–1743.e9. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Busse W: Biological treatments for severe asthma: Where do we stand? Curr Opin Allergy Clin Immunol. 18:509–518. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Mavissakalian M and Brady S: The current state of biologic therapies for treatment of refractory asthma. Clinic Rev Allerg Immunol. 59:195–207. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Xolair® Full Prescribing Information. Genentech. March 21, 2014. Available from: https://www.gene.com/download/pdf/xolair_prescribing.pdf. Accessed August 12, 2021. | |
|
Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, et al: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 356:2144–2148. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Nucala® Full Prescribing Information. GlaxoSmithKline. September 2019. Available from: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF. Accessed August 12, 2021. | |
|
Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H and Chanez P: Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. Lancet. 380:651–659. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, et al: Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 371:1198–1207. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG and Pavord ID: SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 371:1189–1197. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, Yancey SW and Ortega HG: Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: A multi-center, open-label, phase III study. Clin Ther. 38:2058–2070.e1. 2016.PubMed/NCBI View Article : Google Scholar | |
|
US Food, Drug Administration: CINQAIR (reslizumab) Injection, for Intravenous Use. Reference ID: 3906489, 2016. | |
|
European Medicines Agency. EMA/450050/2016. EMEA/H/C/003912. EPAR summary for the public. CINQAERO. INN - reslizumab. https://www.ema.europa.eu/en/documents/overview/cinqaero-epar-summary-public_en.pdf, Accessed May 19, 2021. | |
|
Corren J, Weinstein S, Janka L, Zangrilli J and Garin M: Phase 3 study of reslizumab in patients with poorly controlled asthma: Effects across a broad range of eosinophil counts. Chest. 150:799–810. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O'Brien C and Korn S: Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: Results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 3:355–366. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Murphy K, Jacobs J, Bjermer L, Fahrenholz JM, Shalit Y, Garin M, Zangrilli J and Castro M: Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma. J Allergy Clin Immunol Pract. 5:1572–1581.e3. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, Reed JL, Woods R, Dall'acqua WW, Stephens GL, et al: MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 125:1344–1353.e2. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Pham TH, Damera G, Newbold P and Ranade K: Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 111:21–29. 2016.PubMed/NCBI View Article : Google Scholar | |
|
US Food, Drug Administration: FASENRA (benralizumab) injection, for subcutaneous use. Reference ID: 4181236, 2019. | |
|
European Medicines Agency: EMEA/H/C/4433, 2019. www.ema.europa.eu/en/documents/overview/fasenra-epar-medicine-overview_en.pdf. Accessed 10 May 2021. | |
|
Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, et al: Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): A randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 388:2115–2127. 2016.PubMed/NCBI View Article : Google Scholar | |
|
FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, et al: Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 388:2128–2141. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S and Goldman M: ZONDA Trial Investigators. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 376:2448–2458. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ and Goldman M: BORA study investigators. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 7:46–59. 2019.PubMed/NCBI View Article : Google Scholar | |
|
US Food, Drug Administration. DUPIXENT (dupilumab) injection, for subcutaneous use, 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761055lbl.pdf. Accessed December 11, 2020. | |
|
European Medicines Agency. Dupinex: EMEA/H/C/004390, 2018. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent. Accessed December 1, 2020. | |
|
Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, et al: Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: A randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 388:31–44. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, et al: Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 378:2486–2496. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A, et al: Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 378:2475–2485. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Corren J, Castro M, Ford LB, Bernstein JA, Jayawardena S, Maroni J, Rowe P, Amin N, Pirozzi G, Graham NMH, et al: Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history. Ann Allergy Asthma Immunol. 123:222–224.e1. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Corren J, Castro M, O'Riordan T, Hanania NA, Pavord ID, Quirce S, Chipps BE, Wenzel SE, Thangavelu K, Rice MS, et al: Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. J Allergy Clin Immunol Pract. 8:516–526. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Dupixent® Full Prescribing Information. Regeneron Sanofi Genzyme. January 2021. Available from: https://www.regeneron.com/downloads/dupixent_fpi.pdf. Accessed August 12, 2021. | |
|
Ultsch M, Bevers J, Nakamura G, Vandlen R, Kelley RF, Wu LC and Eigenbrot C: Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. J Mol Biol. 425:1330–1339. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, et al: Lebrikizumab treatment in adults with asthma. N Engl J Med. 365:1088–1098. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, Cheu M, Putnam WS, Murray E, Scheerens H, et al: Lebrikizumab in moderate-to-severe asthma: Pooled data from two randomised placebo-controlled studies. Thorax. 70:748–756. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, She D, Kell C, May RD, Geba GP and Molfino NA: A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 41:330–338. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Brightling CE, Chanez P, Leigh R, O'Byrne PM, Korn S, She D, May RD, Streicher K, Ranade K and Piper E: Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: A randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 3:692–701. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM and van der Merwe R: Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 377:936–946. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Menzies-Gow A, Colice G, Griffiths JM, Almqvist G, Ponnarambil S, Kaur P, Ruberto G, Bowen K, Hellqvist Å, Mo M and Garcia Gil E: NAVIGATOR: A phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir Res. 21(266)2020.PubMed/NCBI View Article : Google Scholar | |
|
Weschler ME, Colice G, Griffiths JM, Almqvist G, Skärby T, Piechowiak T, Kaur P, Bowen K, Hellqvist Å, Mo M and Garcia Gil E: SOURCE: A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma. Respir Res. 21(264)2020.PubMed/NCBI View Article : Google Scholar | |
|
Menzies-Gow A, Ponnarambil S, Downie J, Bowen K, Hellqvist Å and Colice G: DESTINATION: A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir Res. 21(279)2020.PubMed/NCBI View Article : Google Scholar | |
|
Dinarello CA: Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 27:519–550. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Gabryelska A, Kuna P, Antczak A, Białasiewicz P and Panek M: IL-33 mediated inflammation in chronic respiratory diseases-understanding the role of the member of IL-1 superfamily. Front Immunol. 10(692)2019.PubMed/NCBI View Article : Google Scholar | |
|
Efficacy and safety study of GSK3772847 in subjects with moderately severe asthma. ClinicalTrials.gov Identifier: NCT03207243, https://clinicaltrials.gov/ct2/show/NCT03207243. Accessed August 12, 2020. | |
|
Study of REGN3500 and dupilumab in patients with asthma. ClinicalTrials.gov Identifier: NCT03112577, https://clinicaltrials.gov/ct2/show/NCT03112577. Accessed August 12, 2020. | |
|
Dantes E, Fildan AP, Toma CL, Voicu GH and Oancea C: Respiratory impact in workers exposed to air pollutants from petroleum refinery. J Environ Prot Ecol. 17:523–531. 2016. | |
|
Tofolean D, Popescu G, Arghir IA, Frandes M and Fildan AP: A different aproach of chronic obstructive pulmonary disease severity and plastic medical devices used for oxygenotherapy. Mater Plast. 56:295–230. 2019. | |
|
Barsan M, Rajnoveanu AG, Cocarla A, Bolfa P, Login CC, Socaciu AI, Decea N and Leucuta DC: A study of oxidative stress and pulmonary damage after silica instillation in rats and the effect of curcumin administration. Med Pr. 72:239–247. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Trenchea M, Arghir IA, Popescu GG, Rascu S, Bechir ES, Tofolean DE, Fildan AP, Ion I and Dantes E: The triad nocturia, smoking and obstructive sleep apnea. Rev Chim. 70:1839–1842. 2019. | |
|
Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al: International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 43:343–373. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Hogea Stanca P, Tudorache E, Fildan AP, Fira-Mladinescu O, Marc M and Oancea C: Risk factors of chronic obstructive pulmonary disease exacerbations. Clin Respir J. 14:183–197. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Bourdin A, Husereau D, Molinari N, Golam S, Siddiqui MK, Lindner L and Xu X: Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: A systematic review. Eur Respir J. 52(1801393)2018.PubMed/NCBI View Article : Google Scholar | |
|
Casale TB, Pacou M, Mesana L, Farge G, Sun SX and Castro M: Reslizumab compared with benralizumab in patients with eosinophilic asthma: A systematic literature review and network meta-analysis. J Allergy Clin Immunol Pract. 7:122–130.e1. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q, Bratton DJ and Gunsoy NB: Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison. J Allergy Clin Immunol. 143:190–200.e20. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Calzetta L, Matera MG and Rogliani P: Monoclonal antibodies in severe asthma: Is it worth it? Expert Opin Drug Metab Toxicol. 15:517–520. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Edris A, De Feyter S, Maes T, Joos G and Lahousse L: Monoclonal antibodies in type 2 asthma: A systematic review and network meta-analysis. Respir Res. 20(179)2019.PubMed/NCBI View Article : Google Scholar | |
|
Albers F, Liu MC, Chipps BE, Chapman KR, Muñoz X, Bergna M, Devouassoux G, Azmi J, Price R and Galkin D: Therapeutic switch from omalizumab to mepolizumab in patients with uncontrolled severe eosinophilic asthma: Treatment effect by prior omalizumab treatment duration. J Allergy Clin Immunol. 143 (Suppl 2)(AB102)2019. | |
|
Pérez de Llano LA, Cosío BG, Domingo C, Urrutia I, Bobolea I, Valero A, Entrenas Costa LM, Quirce S, Barranco P, Marina Malanda N, et al: Efficacy and safety of reslizumab in patients with severe asthma with inadequate response to omalizumab: A multicenter, open-label pilot study. J Allergy Clin Immunol Pract. 7:2277–2283.e2. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Kavanagh J, Green L, Fernandes M, Roxas C, Kent BD, Jackson DJ and d'Ancona G: Response to benralizumab after sub-optimal response to mepolizumab in oral corticosteroid dependent severe eosinophilic asthma. Am J Respir Crit Care Med. 199(A2675)2019. | |
|
Haldar P, Brightling CE, Singapuri A, Hargadon B, Gupta S, Monteiro W, Bradding P, Green RH, Wardlaw AJ, Ortega H and Pavord ID: Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis. J Allergy Clin Immunol. 133:921–923. 2014.PubMed/NCBI View Article : Google Scholar |
